Reported Earnings • Apr 24
First quarter 2026 earnings released First quarter 2026 results: Revenue: ₩1.26t (down 3.2% from 1Q 2025). Net income: ₩469.0b (up 25% from 1Q 2025). Profit margin: 37% (up from 29% in 1Q 2025). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in South Korea. Announcement • Apr 10
Samsung Biologics Co.,Ltd. to Report Q1, 2026 Final Results on Apr 22, 2026 Samsung Biologics Co.,Ltd. announced that they will report Q1, 2026 final results at 3:00 PM, Korea Standard Time on Apr 22, 2026 Announcement • Apr 02
Samsung Biologics Co.,Ltd. (KOSE : A207940) acquired Manufacturing facility from GSK plc (LSE : GSK). Samsung Biologics Co.,Ltd. (KOSE : A207940) agreed to acquire Manufacturing facility from GSK plc (LSE : GSK) on December 22, 2025.
Samsung Biologics Co.,Ltd. (KOSE : A207940) completed the acquisition of Manufacturing facility from GSK plc (LSE : GSK) on March 31, 2026. Reported Earnings • Feb 28
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: ₩24,091 (up from ₩14,617 in FY 2024). Revenue: ₩4.56t (up 30% from FY 2024). Net income: ₩1.61t (up 55% from FY 2024). Profit margin: 35% (up from 30% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 20%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 14% per year. Announcement • Feb 13
Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 20, 2026 Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 123, central-ro, yeonsu-gu, incheon South Korea Announcement • Feb 06
Samsung Biologics Leads Climate Transparency with Independent Validation of Product Carbon Footprint System Samsung Biologics announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards. The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This reflects the company's advanced and systematically developed approach to carbon accounting across biopharmaceutical manufacturing processes, supporting transparency and consistency in sustainability reporting. The validation was conducted by DNV, an independent assurance and risk management provider headquartered in Norway. DNV assessed the validity of the company's PCF system across data input, conversion, and output, confirming that the assumptions, methods, and overall approach follow globally accepted practices. Through this validated PCF framework, Samsung Biologics aims to support clearer communication and greater comparison of product-level carbon footprint data across the biopharmaceutical value chain, in line with evolving client expectations and sustainability requirements. Reported Earnings • Jan 23
Full year 2025 earnings released: EPS: ₩34,866 (vs ₩23,402 in FY 2024) Full year 2025 results: EPS: ₩34,866 (up from ₩23,402 in FY 2024). Revenue: ₩4.56t (flat on FY 2024). Net income: ₩1.61t (up 49% from FY 2024). Profit margin: 35% (up from 24% in FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Jan 09
Samsung Biologics Co.,Ltd. to Report Fiscal Year 2025 Results on Jan 21, 2026 Samsung Biologics Co.,Ltd. announced that they will report fiscal year 2025 results on Jan 21, 2026 Price Target Changed • Oct 30
Price target increased by 8.4% to ₩1,480,893 Up from ₩1,366,760, the current price target is an average from 25 analysts. New target price is 21% above last closing price of ₩1,221,000. Stock is up 22% over the past year. The company is forecast to post earnings per share of ₩23,755 for next year compared to ₩15,221 last year. Announcement • Oct 28
Samsung Biologics Co.,Ltd. Maintains Revenue Guidance for the Year 2025 Samsung Biologics Co.,Ltd. maintained revenue guidance for the year 2025. The company maintained its annual revenue growth guidance, supported by steady client demand and efficient capacity utilization. Announcement • Oct 17
Samsung Biologics Co.,Ltd. to Report Nine Months, 2025 Results on Oct 28, 2025 Samsung Biologics Co.,Ltd. announced that they will report nine months, 2025 results on Oct 28, 2025 Announcement • Oct 10
Samsung Biologics Introduces Optimized Manufacturing Framework, Exells Samsung Biologics unveiled ExellenSTM - an optimized manufacturing framework applied across the company's biomanufacturing network. Developed through Samsung Biologics' cumulative expertise in plant design, digitalization, and operational excellence, ExellenSTM standardizes equipment, processes, and functional specifications to ensure that every facility operates with the same precision. The framework delivers high-quality, predictable outcomes at speed, empowering clients with faster tech transfers, accelerated approvals, and seamless scaling. ExellenSTM builds on the company's four pillars of excellence in client satisfaction, operations, quality, and people expertise to consistently maintain its manufacturing competitiveness as a pure-play global CDMO. By embedding standardization, simplification, and scalability into every facility, Samsung Biologics is enabling clients to bring life-saving therapies to patients faster and with greater flexibility. Optimized Design for Predictable Outcomes: ExellenS™? integrates Functional Design Specifications (FDS) across all plants, replicating standardized bioreactor configurations and automation systems while allowing tailored improvements for manufacturing execution systems (MES) and continuous innovation. With a proven track record and deep know-how, Samsung Biologics has implemented a unified design model that delivers consistent results while minimizing risks. Accelerating Speed to Market: By ensuring equivalency across facilities, ExellenS™? accelerates global regulatory readiness for clients. Standardized systems reduce risks while streamlined operations minimize changeovers. Agile tech transfers further enable seamless scale-up and on-time product launches. By combining consistency with speed, ExellenS™? provides clients with the flexibility and reliability needed to succeed in a complex global market. Resilience through Standardization: ExellenS™? enhances supply chain continuity by enabling dual-sourcing and multi-plant production. It also integrates unified digital platforms to help clients address challenges with unmatched scale, agility, and resilience. Minimized variability between plants, replicated processes, and universal equipment allow for rapid technology transfers and seamless scale-up, while integrated IT systems ensure compliance and audit readiness. Samsung Biologics currently offers a total manufacturing capacity of 784,000 liters across five plants. Through32, the company plans to add capacity at Bio Campus II, home to its latest Plant 5 that became operational this April. The company also has a dedicated facility for the development and manufacturing of antibody-drug conjugates (ADCs) and global offices to serve clients worldwide. Reported Earnings • Aug 20
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: ₩4,558 (up from ₩4,468 in 2Q 2024). Revenue: ₩1.29t (up 12% from 2Q 2024). Net income: ₩324.4b (up 2.0% from 2Q 2024). Profit margin: 25% (down from 28% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.8%. Earnings per share (EPS) exceeded analyst estimates by 3.8%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Aug 01
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.7% to ₩1,034,000. The fair value is estimated to be ₩1,326,745, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. Announcement • Jul 10
Samsung Biologics Co.,Ltd. to Report First Half, 2025 Results on Jul 23, 2025 Samsung Biologics Co.,Ltd. announced that they will report first half, 2025 results on Jul 23, 2025 Announcement • Jun 18
Samsung Biologics Launches Drug Screening Services, Samsung Organoids Samsung Biologics announced the launch of Samsung Organoids - advanced drug screening services to support clients in drug discovery and development. Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering clinically relevant insights to better understand specific drug responses and improve lead selection. Organoids are emerging as a new research model due to their high similarity to live tissues and potential applications in biomarker discovery and drug efficacy prediction. Samsung Organoidssupport precision screening to predict patient responses, streamline preclinical development, and accelerate timelines toward investigational new drug (IND) filings through data-driven analysis of candidate molecules. With the launch, Samsung Biologics expands its business to include preclinical research, with service offerings spanning target discovery, lead selection, preclinical development, and clinical trial planning. Leveraging its expertise in development and manufacturing, the company will provide data-driven, multi-modal insights into the characteristics and mechanisms of candidate molecules. By helping clients address challenges that may arise during the drug discovery phase, Samsung Biologics aims to enhance clinical success rates. Announcement • Apr 09
Samsung Biologics Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Samsung Biologics Co.,Ltd. announced that they will report Q1, 2025 results at 3:00 PM, Korea Standard Time on Apr 23, 2025 Reported Earnings • Feb 27
Full year 2024 earnings: EPS exceeds analyst expectations Full year 2024 results: EPS: ₩15,221 (up from ₩12,051 in FY 2023). Revenue: ₩4.55t (up 23% from FY 2023). Net income: ₩1.08t (up 26% from FY 2023). Profit margin: 24% (in line with FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.9%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Feb 13
Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 14, 2025 Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 14, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 123, central-ro, yeonsu-gu, incheon South Korea Announcement • Jan 10
Samsung Biologics Co.,Ltd. to Report Fiscal Year 2024 Results on Jan 22, 2025 Samsung Biologics Co.,Ltd. announced that they will report fiscal year 2024 results at 3:00 PM, Korea Standard Time on Jan 22, 2025 Announcement • Jul 11
Samsung Biologics Co.,Ltd. to Report First Half, 2024 Results on Jul 24, 2024 Samsung Biologics Co.,Ltd. announced that they will report first half, 2024 results on Jul 24, 2024 Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Outside Director Eunice Kim was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Apr 10
Samsung Biologics Co.,Ltd. to Report Q1, 2024 Results on Apr 24, 2024 Samsung Biologics Co.,Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024 Reported Earnings • Mar 02
Full year 2023 earnings released: EPS: ₩12,051 (vs ₩11,442 in FY 2022) Full year 2023 results: EPS: ₩12,051 (up from ₩11,442 in FY 2022). Revenue: ₩3.69t (up 23% from FY 2022). Net income: ₩857.7b (up 7.5% from FY 2022). Profit margin: 23% (down from 27% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Feb 22
Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 15, 2024 Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 15, 2024, at 09:01 Korea Standard Time. Location: Songdo ConvensiA Conference Room 113, 1st Floor, Songdo ConvensiA, 123 Central Street, (Yeonsu-gu, Incheon 21998 Korea) Incheon South Korea Agenda: To consider the Approval of the financial statements for the 13th term (01/01/2023- 12/31/2023); To approve the Independent directors Appointment of Suh Seoung-hwan (New appointment); to approve the Audit Committee member Appointment of Suh Seoung-hwan (New appointment); to consider the Approval of the ceiling of remuneration for directors;. Announcement • Jan 10
Samsung Biologics Co.,Ltd. to Report Fiscal Year 2023 Final Results on Jan 24, 2024 Samsung Biologics Co.,Ltd. announced that they will report fiscal year 2023 final results on Jan 24, 2024 Announcement • Oct 12
Samsung Biologics Co.,Ltd. to Report Q3, 2023 Results on Oct 25, 2023 Samsung Biologics Co.,Ltd. announced that they will report Q3, 2023 results on Oct 25, 2023 Announcement • Aug 24
Samsung Biologics Announces Executive Appointments Samsung Biologics announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs. A seasoned pharmaceutical executive, Ward has almost four decades of extensive quality experience in both large pharmaceutical companies and entrepreneurial biotech companies. Prior to joining Samsung Biologics, Ward served as Head of Quality at ProKidney Corporation, a late clinical-stage biotech company specializing in treatments for chronic kidney disease. Her experience also includes quality assurance leadership roles at Celltrion, and senior positions at Diosynth RTP and Biogen. Samsung Biologics also appointed Sojeong Lee as the Vice President and Head of Regulatory Affairs to oversee and manage the company's response to and relationship with global regulatory agencies. Prior to this role, Lee served as the Regulatory Affairs Director at GlaxoSmithKline in Korea. Announcement • Jul 13
Samsung Biologics Co.,Ltd. to Report Q2, 2023 Results on Jul 26, 2023 Samsung Biologics Co.,Ltd. announced that they will report Q2, 2023 results on Jul 26, 2023 Reported Earnings • May 20
First quarter 2023 earnings released: EPS: ₩1,992 (vs ₩2,221 in 1Q 2022) First quarter 2023 results: EPS: ₩1,992 (down from ₩2,221 in 1Q 2022). Revenue: ₩720.9b (up 41% from 1Q 2022). Net income: ₩141.8b (down 3.5% from 1Q 2022). Profit margin: 20% (down from 29% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jan 28
Consensus revenue estimates increase by 12% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩3.15b to ₩3.54b. EPS estimate increased from ₩10,084 to ₩11,175 per share. Net income forecast to grow 52% next year vs 34% growth forecast for Life Sciences industry in South Korea. Consensus price target broadly unchanged at ₩1,107,849. Share price was steady at ₩809,000 over the past week. Reported Earnings • Nov 18
Third quarter 2022 earnings released: EPS: ₩1,815 (vs ₩1,992 in 3Q 2021) Third quarter 2022 results: EPS: ₩1,815 (down from ₩1,992 in 3Q 2021). Revenue: ₩873.0b (up 94% from 3Q 2021). Net income: ₩129.2b (down 2.0% from 3Q 2021). Profit margin: 15% (down from 29% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in Asia. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Major Estimate Revision • Oct 28
Consensus revenue estimates increase by 16% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from ₩2.57b to ₩2.98b. EPS estimate increased from ₩8,647 to ₩8,901 per share. Net income forecast to grow 34% next year vs 34% growth forecast for Life Sciences industry in South Korea. Consensus price target broadly unchanged at ₩1,101,387. Share price rose 3.4% to ₩876,000 over the past week. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: ₩2,160 (vs ₩1,837 in 2Q 2021) Second quarter 2022 results: EPS: ₩2,160 (up from ₩1,837 in 2Q 2021). Revenue: ₩651.4b (up 58% from 2Q 2021). Net income: ₩152.0b (up 25% from 2Q 2021). Profit margin: 23% (down from 30% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 36% growth forecast for the Life Sciences industry in South Korea. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Aug 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Geunnyeong Heo was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Jul 28
Consensus EPS estimates increase by 13% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₩2.10b to ₩2.17b. EPS estimate increased from ₩7,373 to ₩8,295 per share. Net income forecast to grow 24% next year vs 39% growth forecast for Life Sciences industry in South Korea. Consensus price target broadly unchanged at ₩1,092,923. Share price rose 5.6% to ₩863,000 over the past week. Board Change • Jul 03
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Geunnyeong Heo was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 22
First quarter 2022 earnings: Revenues exceed analyst expectations First quarter 2022 results: Revenue: ₩511.3b (up 96% from 1Q 2021). Net income: ₩146.9b (up 141% from 1Q 2021). Profit margin: 29% (up from 23% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 10%. Over the next year, revenue is forecast to grow 13%, compared to a 37% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 21
Samsung Biologics Co.,Ltd. (KOSE:A207940) completed the acquisition of the remaining 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB). Samsung Biologics Co.,Ltd. (KOSE:A207940) reached an agreement to acquire the remaining 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB) for $2.3 billion on January 27, 2022. Samsung Biologics Co.,Ltd shall acquire 50% less 1 share equivalent to 10.341852 million held by Biogen Inc. The Board of Directors of Samsung Biologics has approved the transaction, in which payment for the shares will be made in installments over the next two years, and full ownership will take effect at the time the first payment of $1 billion is made. Under the terms of this agreement, Biogen will receive $1 billion in cash at closing and $1.25 billion to be deferred over two payments of $812.5 million due at the first anniversary and $437.5 million due at the second anniversary of the closing of the transaction. Biogen is eligible to receive up to $50 million contingent upon achievement of certain commercial milestones. Upon the acquisition of Biogen’s stake, the companies will continue with their exclusive agreements, including commercialization of their current portfolio. This includes marketed products BENEPALI® (etanercept), a biosimilar referencing ENBREL®, IMRALDITM (adalimumab), a biosimilar referencing Humira®, and FLIXABI® (infliximab), a biosimilar referencing Remicade®. Additionally, Biogen will also retain commercial rights for BYOOVIZTM (ranibizuman-nuna), an approved biosimilar referencing LUCENTIS® (ranibizumab), as well as an investigational biosimilar candidate in development, SB15 (aflibercept), a proposed biosimilar referencing EYLEA. Closing of the transaction is contingent on the effectiveness of a securities registration statement filed by Samsung Biologics and satisfaction of certain regulatory and other customary closing conditions. As on April 6, 2022, European Commission has approved the transaction. The Board of Samsung Biologics Co.,Ltd. has also agreed to raise capital of $2.5 billion by issuing new shares, the proceeds of which will be used to fund the company's strategic growth plans, including the purchase of the Samsung Bioepis shares. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis. The stake transfer will take place on April 30, 2022. Transaction projected to be accretive to earnings in 2022.
Moelis & Company (NYSE:MC) acts as financial advisor to Biogen, inc. Kim & Chang and Anne Wachsmann and Nicolas Zacharie of Linklaters acted as legal advisors of Samsung Biologics.
Samsung Biologics Co.,Ltd. (KOSE:A207940) completed the acquisition of the remaining 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB) on April 20, 2022. Announcement • Mar 29
Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 29, 2022 Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 29, 2022, at 09:00 Korea Standard Time. Location: Incheon Global Campus (Auditorium) Songdomunhwaro-119,Yeonsu-gu Icheon South Korea Agenda: To consider Approval of Audited Financial Statements (FY2021); to consider Election of Directors , Appointment of Executive Director : Mr. Dong Joong KIM (Re-nominated), Appointment of Independent Director : Mr. Kun Nyoung HUH (Re-nominated), Appointment of Independent Director : Mr. Jae Wan BAHK (Newly-nominated); to consider Election of Director as Audit Committee Member, Appointment of Independent Director : Mr. Chang Woo LEE (Newly-nominated); to consider Election of Audit Committee Member, Appointment of Independent Director : Mr. Kun Nyoung HUH (Re-nominated), Appointment of Independent Director : Ms. Eunice Kyonghee KIM (Newly-nominated); and to consider Approval of Director Remuneration Limit (FY2022). Announcement • Jan 29
Samsung Biologics Co.,Ltd. (KOSE:A207940) reached an agreement to acquire 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB) for $2.3 billion. Samsung Biologics Co.,Ltd. (KOSE:A207940) reached an agreement to acquire 49.9% stake in Samsungbioepis Co,.Ltd from Biogen Inc. (NasdaqGS:BIIB) for $2.3 billion on January 27, 2022. Samsung Biologics Co.,Ltd shall acquire 50% less 1 share held by Biogen Inc. The Board of Directors of Samsung Biologics has approved the transaction, in which payment for the shares will be made in installments over the next two years, and full ownership will take effect at the time the first payment of USD $1.0 billion is made. Under the terms of this agreement, Biogen will receive $1 billion in cash at closing and $1.25 billion to be deferred over two payments of $812.5 million due at the first anniversary and $437.5 million due at the second anniversary of the closing of the transaction. Biogen is eligible to receive up to $50 million contingent upon achievement of certain commercial milestones. Upon the acquisition of Biogen’s stake, the companies will continue with their exclusive agreements, including commercialization of their current portfolio. This includes marketed products BENEPALI® (etanercept), a biosimilar referencing ENBREL®, IMRALDITM (adalimumab), a biosimilar referencing Humira®, and FLIXABI® (infliximab), a biosimilar referencing Remicade®. Additionally, Biogen will also retain commercial rights for BYOOVIZTM (ranibizuman-nuna), an approved biosimilar referencing LUCENTIS® (ranibizumab), as well as an investigational biosimilar candidate in development, SB15 (aflibercept), a proposed biosimilar referencing EYLEA. Closing of the transaction is contingent on the effectiveness of a securities registration statement filed by Samsung Biologics and satisfaction of certain regulatory and other customary closing conditions. The Board of Samsung Biologics Co.,Ltd. has also agreed to raise capital of $2.5 billion by issuing new shares, the proceeds of which will be used to fund the company's strategic growth plans, including the purchase of the Samsung Bioepis shares. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis. Transaction projected to be accretive to earnings in 2022. Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS ₩1,992 (vs ₩848 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₩450.7b (up 64% from 3Q 2020). Net income: ₩131.8b (up 135% from 3Q 2020). Profit margin: 29% (up from 20% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 24
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA Samsung Biologics introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seamless drug development solution resulting in accelerated timelines. S-CellerateTM is a drug development service platform which offers an expedited process for the development and commercialization of monoclonal antibodies. This platform includes two distinguished services: an accelerated CDO timeline to Investigational New Drug Application (IND), and a complete solution for commercialization to reach Biologics License Applications (BLA). With S-CellerateTM, clients are able to reach IND filings in as fast as 9 months, as well as access a full spectrum of services from process characterization and validation to BLA submission while maintaining the highest product quality and operational robustness. The company’s CDO business brings quality-driven development services at a greater speed. The company also operates a global R&D center in San Francisco, California, and with the launch of S-CellerateTM, along with its proprietary cell line development platform S-CHOiceTM, Samsung Biologics continues to provide competitive and innovative service offerings to clients, accelerating the speed of molecules to market. Announcement • Sep 13
Samsung Biologics Joins Frontier 1.5D Project as Part of 2050 Carbon Neutral Initiative Samsung Biologics announced the signing of an MOU to participate in the Frontier 1.5D initiative to develop a climate risk management model as part of 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change. The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels, and local business leaders have joined forces with the British Embassy, Ewha Woman's University, Financial Supervisory Service, to collectively thrive for a net-zero future. Frontier 1.5D is expected to address uncertainties associated with climate change by analyzing the financial impact of climate change and climate response policies such as GHG reductions. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS ₩1,837 (vs ₩786 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₩412.2b (up 34% from 2Q 2020). Net income: ₩121.5b (up 134% from 2Q 2020). Profit margin: 30% (up from 17% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 23
First quarter 2021 earnings released: EPS ₩922 (vs ₩554 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩260.8b (up 26% from 1Q 2020). Net income: ₩61.0b (up 66% from 1Q 2020). Profit margin: 23% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 05
Full year 2020 earnings released: EPS ₩3,642 (vs ₩3,067 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: ₩1.16t (up 66% from FY 2019). Net income: ₩241.0b (up 19% from FY 2019). Profit margin: 21% (down from 29% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Feb 27
Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 19, 2021 Samsung Biologics Co.,Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Feb 18
New 90-day low: ₩783,000 The company is down 2.0% from its price of ₩799,000 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩63,488 per share. Announcement • Jan 21
Samsung Biologics Co.,Ltd. to Report Fiscal Year 2020 Results on Jan 26, 2021 Samsung Biologics Co.,Ltd. announced that they will report fiscal year 2020 results on Jan 26, 2021 Is New 90 Day High Low • Dec 04
New 90-day high: ₩825,000 The company is up 7.0% from its price of ₩773,000 on 04 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩51,004 per share. Announcement • Nov 18
Samsung Biologics Announces Strategic Manufacturing Partnership with Lilly to Accelerate Delivery of COVID-19 Antibody Treatments Samsung Biologics' partnership with Eli Lilly and Company is expected to greatly accelerate the global supply for Lilly's COVID-19 antibody therapies through a long-term manufacturing agreement, with the ultimate goal of making antibody treatments more globally accessible for patients. Announcement • Nov 14
FibroGen, Inc. Enters into a Master Services Agreement with Samsung Biologics Co., Ltd FibroGen Inc. announced that it has entered into a Master Services Agreement with Samsung Biologics Co. Ltd., pursuant to which Samsung will provide FibroGen with certain biologics manufacturing services in accordance with one or more product specific agreements. The MSA shall remain in effect for so long as a product specific agreement is in effect. The MSA contains standard termination clauses for material breach and insolvency, as well as standard indemnification obligations of FibroGen and of Samsung. In connection with the MSA, on November 9, 2020, FibroGen and Samsung entered into a product specific agreement (the “PSA”) for the manufacturing and supply of pamrevlumab drug substance, for clinical and commercial use. The PSA contains product purchase and manufacturing commitments on the part of FibroGen and Samsung, respectively, over the next two years, invoiced on a per-batch basis, as well as technology transfer and other related services. The PSA contains customary limitations on liability, and performance of services thereunder is subject to the terms of the MSA. Announcement • Nov 03
Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab Samsung Biologics Co. Ltd. and Checkpoint Therapeutics, Inc. announced the expansion of a long-term manufacturing partnership for Checkpoint's anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint. Under the new agreement, Samsung Biologics will commence manufacturing in 2021 in Plant 1. Samsung Biologics recently announced it will break ground on its fourth plant within this year to commence manufacturing activities in the latter half of 2022, deliver world-class client satisfaction, and fulfill the needs of the growing biopharmaceutical market. Announcement • Nov 02
Samsung Biologics Establishes Partnership with GeneQuantum Healthcare to Collaborate on ADC Development Samsung Biologics has entered into a strategic partnership with GeneQuantum Healthcare, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors. The agreement signals Samsung Biologics' accelerated entry into the China market. GeneQuantum Healthcare recently received the US FDA's Investigational New Drug (IND) Good to Proceed Letter in May this year for its first anti-HER2 ADC asset, which was manufactured via GeneQuantum's patented intelligent ligase-dependent conjugation (iLDC) technology platform. Is New 90 Day High Low • Oct 22
New 90-day low: ₩658,000 The company is down 13% from its price of ₩755,000 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 8.0% over the same period. Announcement • Oct 16
Samsung Biologics Co.,Ltd. to Report Nine Months, 2020 Results on Oct 21, 2020 Samsung Biologics Co.,Ltd. announced that they will report nine months, 2020 results on Oct 21, 2020 Announcement • Sep 24
Samsung Biologics Signs Strategic Partnership with Kanaph Therapeutics to Develop Treatment for Retinal Diseases Samsung Biologics and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases. According to Kanaph Therapeutics, KNP-301 is designed to target autoimmune diseases by inhibiting the alternative pathway of the complement system. With the benefits of its bi-specific approach, it aims to successfully treat complement-mediated and angiogenesis driven retinal diseases by suppressing both C3b and VEGF simultaneously. Under the agreement, Samsung Biologics will provide a full scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission. Is New 90 Day High Low • Sep 24
New 90-day low: ₩705,000 The company is down 13% from its price of ₩815,000 on 25 June 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 6.0% over the same period. Announcement • Sep 22
Samsung Biologics and Astrazeneca Forge Strategic Manufacturing Partnership for Global Supply Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca's biologics therapeutics, which could be increased to $545.6 million. By leveraging Samsung Biologics' robust expertise and capabilities in the manufacturing of high-quality biopharmaceuticals, this new partnership will enable AstraZeneca to expand its biologics manufacturing capabilities into Asia Pacific. According to AstraZeneca, this collaboration agreement is also expected to accelerate Korean bio-health innovation. Announcement • Sep 17
Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing. According to Panolos, PB101 is expected to suppress tumor angiogenesis more effectively by targeting VEGF-A and PlGF simultaneously, overcoming the limitations of existing treatments. Leveraging Samsung Biologics' robust capabilities and expertise in developing complex proteins, Panolos intends to achieve successful IND approval for validation to further establish the substance as the new platform known as aARTTM(anti-angiogenesis-based Artifact Re-targeting Tri-specifics) to treat various VEGF related illnesses. Announcement • Jul 18
Samsung Biologics Co.,Ltd. to Report First Half, 2020 Results on Jul 21, 2020 Samsung Biologics Co.,Ltd. announced that they will report first half, 2020 results on Jul 21, 2020